Inhibitors of UDP-galactopyranose mutase
AssigneeWisconsin Alumni Research Foundation
InventorsLaura L. Kiessling, Virginia A. Kincaid, Nir London, Brian K. Shoichet
Life of this patent
Estimating the term…
Loading patent…
AssigneeWisconsin Alumni Research Foundation
InventorsLaura L. Kiessling, Virginia A. Kincaid, Nir London, Brian K. Shoichet
Estimating the term…
Compounds and salts thereof which inhibit microbial growth or attenuate the virulence of pathogenic microorganisms and which inhibit UDP-galactopyranose mutase (UGM). Compounds of the invention include triazolothiadiazines, particularly 3, 6, 7-substituted-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines, and 4-(1H-pyrrol-3-yl) thiazoles, particularly 4-(1,2,5-substituted-1H-pyrrol-3-yl)-2-substituted thiazoles, and salts thereof. Methods for inhibiting growth or attenuating virulence of microbial pathogens including mycobacterium, for example, M. tuberculosis and M. smegmatis and Klebsiella, for example, Klebsiella pneumoniae. Methods for inhibiting eukaryotic human and animal pathogens, and fungi and nematodes in particular. Methods for treatment of infections by prokaryotic and eukaryotic pathogens employing compounds of the invention.
A method for inhibiting uridine 5′-diphosphate-galactopyranose mutase (UGM) which comprises contacting UGM with an amount of one or more compounds of formula II or salts thereof effective for inhibiting the enzyme wherein
A method for inhibiting the growth of a microorganism which comprises contacting the microorganism or an environment containing the microorganism with an effective amount of one or more compounds formula II or salts thereof as defined herein, wherein
A method of treating an infection by a microorganism having UGM in an individual in need of such treatment by administering to the individual an effective amount of one or more compounds of formula II or salts thereof, wherein:
A pharmaceutically acceptable composition which comprises one or more compounds of formula II or salts thereof and a pharmaceutically acceptable carrier wherein formula II is
A compound of formula II or a salt thereof, wherein formula II is
A compound of formula II:
Dependencies are inferred from the claim text.